BNET Industries

BNET Pharma

Industry news and insights by Jim Edwards

Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More

By John Maas | January 5th, 2009 @ 5:09 pm

Pfizer CEO seeks big acquisition — In a much-discussed comment to the Financial Times, Pfizer’s CEO Jeff Kindler revealed his aspirations for revenue-boosting deals, large and small. As the Health Blog points out, the takeaway here is Kindler’s apparent willingness to pursue old-fashioned big acquisitions, at a time when most pharma companies seem interested in smaller purchases, if any. Derek Lowe at In the Pipeline is unimpressed. [Source: WSJ Health Blog]

Prasugrel to be reviewed on February 3 — The FDA has granted a formal hearing to the drug, a Lilly and Daiichi product currently languishing in a quagmire of delay. Lilly has high hopes for the drug. [Source: PharmaTimes]

Resolutions, predictions, and other New Year’s features — Bloggers love lists, and the dawn of 2009 brings us end-of-year/New Year features from many sites. Highlights include Fierce Biotech’s dire “Welcome to the valley of death” biotech check-in and John Mack’s cheeky “resolutions” for pharma marketers. [Source: FierceBiotech, Pharma Marketing Blog]

Pharmalot’s swan song — As many of you may know, Ed Silverman has penned the final post at pharmaceuticals blog Pharmalot . For the past two years, Ed has brought us sharp, savvy analysis of timely industry news, and Pharmalot has been a consistent voice of quality in the pharma blogosphere. Thank you, Ed… we wish you all the best! Pharmalot will be missed. [Source: Pharmalot]

Tags: Acquisition, Pfizer Inc., Pharmaceutical Company, Lilly, Pharmalot, John Maas

 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
  2.  
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement
AboutPharma Industry

BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.